Abstract
In spite of the improvements in transfusion safety occurred in the last decades, platelet septic transfusions still represent a cause for concern. Microbial screening of blood products cannot ensure transfusion sterility, so that pathogen inactivation methods and a timely management of infectious events actually play the most relevant role. Biofilm production has been associated to several human illnesses; also, it promotes bacterial adherence to platelet bags and colonization of recipients catheter after transfusion. Therefore, facing biofilm communities is required to reduce the contamination risk and the occurrence of post-infusion events. In this context, the use of tigecycline as a wide-spectrum antibiofilm drug is discussed, along with recent patents about biofilm treatment by quorum-sensing blockers, bacteriophage-based therapy and antibiofilm oral compounds.
Keywords: Transfusion, platelet, biofilm, bacteremia, sepsis, septicaemia, tigecycline, glycylglycine
Recent Patents on Anti-Infective Drug Discovery
Title: Bacterial Contamination of Platelets and Septic Transfusions: Review of the Literature and Discussion on Recent Patents About Biofilm Treatment
Volume: 5 Issue: 2
Author(s): Vincenzo Savini, Chiara Catavitello, Daniela Astolfi, Andrea Balbinot, Gioviana Masciarelli, Arianna Pompilio, Anna M. Quaglietta, Patrizia Accorsi, Giovanni Di Bonaventura, Claudio D'Amario, Domenico D'Antonio and Antonio Iacone
Affiliation:
Keywords: Transfusion, platelet, biofilm, bacteremia, sepsis, septicaemia, tigecycline, glycylglycine
Abstract: In spite of the improvements in transfusion safety occurred in the last decades, platelet septic transfusions still represent a cause for concern. Microbial screening of blood products cannot ensure transfusion sterility, so that pathogen inactivation methods and a timely management of infectious events actually play the most relevant role. Biofilm production has been associated to several human illnesses; also, it promotes bacterial adherence to platelet bags and colonization of recipients catheter after transfusion. Therefore, facing biofilm communities is required to reduce the contamination risk and the occurrence of post-infusion events. In this context, the use of tigecycline as a wide-spectrum antibiofilm drug is discussed, along with recent patents about biofilm treatment by quorum-sensing blockers, bacteriophage-based therapy and antibiofilm oral compounds.
Export Options
About this article
Cite this article as:
Savini Vincenzo, Catavitello Chiara, Astolfi Daniela, Balbinot Andrea, Masciarelli Gioviana, Pompilio Arianna, M. Quaglietta Anna, Accorsi Patrizia, Di Bonaventura Giovanni, D'Amario Claudio, D'Antonio Domenico and Iacone Antonio, Bacterial Contamination of Platelets and Septic Transfusions: Review of the Literature and Discussion on Recent Patents About Biofilm Treatment, Recent Patents on Anti-Infective Drug Discovery 2010; 5 (2) . https://dx.doi.org/10.2174/157489110791233531
DOI https://dx.doi.org/10.2174/157489110791233531 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Berberine Inhibits the Gene Expression and Production of Proinflammatory Cytokines by Mononuclear Cells in Rheumatoid Arthritis and Healthy Individuals
Current Rheumatology Reviews Cytotoxicity, Anti-diabetic, and Hepato-protective Potential of <i>Ajuga bracteosa</i>-conjugated Silver Nanoparticles in Balb/c Mice
Current Pharmaceutical Biotechnology Systemic Fungal Infections Caused by Candida Species: Epidemiology, Infection Process and Virulence Attributes
Current Drug Targets Oxidative Stress, Endothelial Dysfunction and Atherosclerosis
Current Pharmaceutical Design Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews Efficacy and Cardiovascular Safety of SGLT2 Inhibitors
Current Drug Safety TRPV1 and TRPA1 in Pulmonary Vagal Afferents and their Relations to Airway Sensitivity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Current Pharmaceutical Design Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
Current Medicinal Chemistry Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets Total Ankle Replacement in Hemophilia
Cardiovascular & Hematological Disorders-Drug Targets Anti-Candida Activity of Curcumin: A Systematic Review
Current Drug Discovery Technologies Nasal Air-Conditioning During Breathing Therapy
Current Respiratory Medicine Reviews Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis
Recent Patents on Biomedical Engineering (Discontinued) Effects of Synthetic Peptides on the Inflammatory Response and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Pharmacogenomics in the Intensive Care Unit: Focus on Potential Implications for Clinical Practice
Recent Patents on Biotechnology The Epidemiology of Sepsis
Current Pharmaceutical Design The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development
Current Drug Metabolism